Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rislenemdaz - Avalo Therapeutics

Drug Profile

Rislenemdaz - Avalo Therapeutics

Alternative Names: AVTX-301; CERC-301; MK-0657

Latest Information Update: 28 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Avalo Therapeutics; Merck & Co
  • Class Amines; Antidepressants; Antihypotensives; Antiparkinsonians; Esters; Piperidines; Pyrimidines
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • No development reported Orthostatic hypotension
  • Discontinued Parkinson's disease

Most Recent Events

  • 28 Sep 2021 No recent reports of development identified for phase-I development in Orthostatic-hypotension in USA (PO)
  • 26 Aug 2021 Cerecor is now called Avalo Therapeutics
  • 28 May 2021 Alto Neuroscience in-licenses CERC 301 from Cerecor
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top